Domiciliary Monitoring to Predict Exacerbations of COPD

COPD Exacerbation Clinical Trial

Official title:

Domiciliary Monitoring to Predict Exacerbations of COPD

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03003702
• Other study ID #: 16/LO/1120
• Status: Completed
• Phase: N/A
• Start date: September 2016
• Est. completion date: April 2018

Study information

• Verified date: October 2018
• Source: University College, London
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Chronic Obstructive Pulmonary Disease (COPD) is a common, long term condition of the lungs that is usually caused by cigarette smoking. In addition to daily symptoms and limitation in activities, patients are prone to developing chest infections called 'exacerbations'. Exacerbations are a big problem: unpleasant for patients, and sometimes severe enough to cause hospital admission (and therefore health facilities pressures) and death. Reducing the impact of exacerbations is very important. Investigators have previously shown that earlier treatment of COPD exacerbations results in faster recovery, and reduced chance of hospital admission. Helping patients to detect exacerbations early is therefore important. Investigators have also recently shown that monitoring heart rate and oxygen saturation via a finger probe may assist in this. However, measuring these variables when the patient is awake means they can be affected by other things, such as exercise and anxiety. Our new idea is that measuring heart rate and oxygen level overnight, when a patient is asleep, will give the best chance of detecting COPD exacerbations early and our study will test that. Investigators will randomly allocate 77 patients with COPD recruited from our service in London to standard monitoring, or overnight monitoring, for up to six months or the first exacerbation, whichever is sooner. Investigators will then analyse whether overnight monitoring was able to detect exacerbations earlier, and therefore could be used to help patients get treatment earlier. A subset of participants will also wear an activity monitor overnight for the first two weeks, so that Investigators can assess the effect (if any) of overnight awake periods (such as trips to the bathroom) on the heart rate and saturation recording.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 85
• Est. completion date: April 2018
• Est. primary completion date: April 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 90 Years

Eligibility

Inclusion Criteria:

1. Patient diagnosed with COPD (smoking history of =10 pack years and FEV1/VC < 0.7 post-bronchodilator).

2. Patient who had two or more self-reported moderate or severe COPD exacerbations in the past 12 months.

3. Patient who can use study equipment and attend appointments.

4. Can communicate in English.

Exclusion Criteria:

1. Patient who was diagnosed with obstructive sleep apnea (through a self-report and/or a result of Stop Bang and Epworth questionnaires).

2. Patient with co-morbidity preventing taking part.

3. Patients already involved in an ongoing research study.

Related Conditions & MeSH terms

• COPD Exacerbation

Intervention

Device:
• Nonin

Locations

Country	Name	City	State
United Kingdom	Royal Free Hospital NHS	London

Sponsors (1)

Lead Sponsor	Collaborator
University College, London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary outcome is the difference in time to receive treatment from exacerbation onset as defined by symptoms, compared to exacerbation onset as defined by change in physiology		6 months